Novo Nordisk's Christmas Gift To Shareholders: The Wegovy Pill Has Been Approved (NVO)

Core Insights - The oral semaglutide (Wegovy pill) has received FDA approval, marking a significant milestone for Novo Nordisk A/S, which could be a turning point for the company [1]. Company Summary - Novo Nordisk A/S is positioned to benefit from the FDA approval of the oral semaglutide, which is expected to enhance its market presence and potentially drive revenue growth [1].